# Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)

> **NCT02947438** · PHASE3 · COMPLETED · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 207 (actual)

## Conditions studied

- Renal Anemia

## Interventions

- **DRUG:** EPREX®
- **DRUG:** EPIAO®

## Key facts

- **NCT ID:** NCT02947438
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2021-10-09
- **Final completion:** 2021-10-09
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2022-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947438, "Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02947438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*